Literature DB >> 2004862

Treatment of Alzheimer's disease with cholinergic drugs.

V Kumar1, M Calache.   

Abstract

Several cholinergic drugs have been experimentally used to treat the cognitive and behavioral deficits associated with Alzheimer's disease. Unfortunately the results have been somewhat disappointing. The cholinergic drugs are also prone to produce serious side effects. Experience with these drugs lead us to conclude that cholinergic drugs alone may not be the answer to treat Alzheimer disease patients. There seems to be a need to develop drug(s) which could affect several neurotransmitter or neuromodulator systems. Neuroendocrine changes induced by these drugs may be useful biological markers in estimating their central effects.

Entities:  

Mesh:

Substances:

Year:  1991        PMID: 2004862

Source DB:  PubMed          Journal:  Int J Clin Pharmacol Ther Toxicol        ISSN: 0174-4879


  5 in total

1.  Cholinergic nicotinic systems in Alzheimer's disease: prospects for pharmacological intervention.

Authors:  Robyn Vesey; Jennifer M Birrell; Clare Bolton; Ruth S Chipperfield; Andrew D Blackwell; Tom R Dening; Barbara J Sahakian
Journal:  CNS Drugs       Date:  2002       Impact factor: 5.749

2.  Effect of the putative cognitive enhancer, linopirdine (DuP 996), on quantal parameters of acetylcholine release at the frog neuromuscular junction.

Authors:  S D Provan; M D Miyamoto
Journal:  Br J Pharmacol       Date:  1994-04       Impact factor: 8.739

3.  Pharmacokinetics of physostigmine in man following a single application of a transdermal system.

Authors:  K Walter; M Müller; M F Barkworth; A V Nieciecki; F Stanislaus
Journal:  Br J Clin Pharmacol       Date:  1995-01       Impact factor: 4.335

4.  Beta-adrenoceptor density and subtype distribution in cerebellum and hippocampus from patients with Alzheimer's disease.

Authors:  B Lemmer; L Langer; T Ohm; J Bohl
Journal:  Naunyn Schmiedebergs Arch Pharmacol       Date:  1993-02       Impact factor: 3.000

5.  PD 142676 (CI 1002), a novel anticholinesterase and muscarinic antagonist.

Authors:  M R Emmerling; V E Gregor; R D Schwarz; J D Scholten; M J Callahan; C Lee; C J Moore; C Raby; W J Lipinski; R E Davis
Journal:  Mol Neurobiol       Date:  1994 Aug-Dec       Impact factor: 5.590

  5 in total

北京卡尤迪生物科技股份有限公司 © 2022-2023.